State of Hepatitis in the USA

🏆 States on‑track to eliminate HCV by 2030

A 2020–17 model projected only three states—Connecticut, South Carolina, and Washington—are on pace to meet all WHO HCV elimination targets (diagnosis, treatment, incidence, mortality) by 2030

---

💊 Medicaid innovations & treatment access

Maryland launched a Medicaid–Medicare cost-sharing model: Medicaid funds DAA therapy early, and Medicare repays savings later—estimating savings of $158–178 per patient annually .

Louisiana and Washington introduced “subscription” payment models, enabling unlimited DAA (see below image re: DAA, DAA (direct-acting antiviral) therapy is a highly effective treatment for HCV infection, offering a high chance of cure with oral medication. It works by targeting specific HCV proteins, disrupting viral replication and leading to a sustained virologic response aka SVR).stands for treatment for a fixed fee, extending access to Medicaid and incarcerated populations.

By early 2024, 29 states (including AK, CA, CO, CT, FL, HI, IL, IN, MA, NY, OR, TX, WA) had eliminated prior‑authorization and liver‑damage restrictions for HCV treatment in Medicaid. This broad removal of barriers marks a nationwide innovation in access.

---

🧬 Other hepatitis efforts and public‑health campaigns

• San Francisco, California, launched “Hep B Free” in 2007, the first citywide hepatitis B elimination campaign in the U.S., focused on screening and vaccination in high‑risk API communities
• States like Florida, Illinois, and Hawaii each developed comprehensive elimination strategies—e.g., Florida’s statewide HCV elimination group, Chicago’s culturally‑tailored Hep B programs, and Hawaii’s “Hep Free 2030” initiative.

---

🌐 Heavy-hitting biotech innovation hubs

States with strong biotech and pharmaceutical infrastructure—notably Massachusetts, California, Maryland, and Delaware—support hepatitis innovation through research labs, drug development, and gene therapy efforts.

Maryland, in particular, benefits from its “DNA Valley” corridor around NIH facilities in Bethesda, which fosters cutting‑edge genetic and viral‑vector research potentially impacting hepatitis therapies.

---

✅ Summary Table

State	Notable Innovation
Connecticut, SC, Washington	On schedule for WHO HCV elimination targets by 2030
Maryland	Medicaid–Medicare cost-sharing model for DAA treatment
Louisiana, Washington	Subscription-based payment for unlimited DAA access
~29 states	Removed Medicaid treatment barriers for HCV by early 2024
San Francisco (CA)	Pioneering citywide Hep B elimination campaign
Florida, Illinois, Hawaii	Statewide public-health hepatitis plans
MA, CA, MD, DE	Leading biotech/pharma hubs supporting hepatitis research

a